• 1
    Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:12061252.
  • 2
    Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:11051187.
  • 3
    Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet. 2004;363:20492051.
  • 4
    Parving HH, Persson F, Lewis JB, et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008;358:24332446.
  • 5
    McMurray J, Pitt B, Latini R, et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail. 2008;1:1724.
  • 6
    Solomon SD, Appelbaum E, Manning WJ, et al. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation. 2009;119:530537.
  • 7
    Littlejohn TW III, Trenkwalder P, Hollanders G, et al. Long-term safety, tolerability and efficacy of combination therapy with aliskiren and amlodipine in patients with hypertension. Curr Med Res Opin. 2009;25:951959.
  • 8
    Drummond W, Munger MA, Essop MR, et al. Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy. J Clin Hypertens. 2007;9:742750.
  • 9
    Villamil A, Chrysant SG, Calhoun D, et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens. 2007;25:217226.
  • 10
    Andersen K, Weinberger MH, Egan B, et al. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial. J Hypertens. 2008;26:589599.
  • 11
    Uresin Y, Taylor AA, Kilo C, et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst. 2007;8:190198.
  • 12
    Oparil S, Yarows SA, Patel S, et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet. 2007;370:221229.
  • 13
    Chrysant SG, Murray AV, Hoppe UC, et al. Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis. Curr Med Res Opin. 2008;24:10391047.
  • 14
    White W, Bresalier R, Kaplan A, et al. Safety and tolerabililty of aliskiren: a pooled analysis of clinical experience in over 12000 patients. J Clin Hypertens. 2010;12(10):765775.
  • 15
    NCT00344110. Study comparing SPP100 (aliskiren) 150 mg to placebo and to losartan 50 mg in patients with mild to moderate essential hypertension. .
  • 16
    Kushiro T, Itakura H, Abo Y, et al. Aliskiren, a novel oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in Japanese patients with hypertension. Hypertens Res. 2006;29:9971005.
  • 17
    Gradman AH, Schmieder RE, Lins RL, et al. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation. 2005;111:10121018.
  • 18
    Pool JL, Schmieder RE, Azizi M, et al. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens. 2007;20:1120.
  • 19
    Oh BH, Mitchell J, Herron JR, et al. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol. 2007;49:11571163.
  • 20
    Puig JG, Schunkert H, Taylor A, et al. Evaluation of the dose-response relationship of aliskiren, a direct renin inhibitor, in an 8-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled study in adult patients with stage 1 or 2 essential hypertension. Clin Ther. 2009;31:28392850.
  • 21
    NCT00706134. Efficacy and safety of aliskiren 75 mg, 150 mg and 300 mg in elderly patients with essential hypertension when given with a light meal in a 8 week placebo-controlled study. .
  • 22
    Schmieder RE, Philipp T, Guerediaga J, et al. Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide. Circulation. 2009;119:417425.
  • 23
    Duprez DA, Munger MA, Botha J, et al. Aliskiren for Geriatric Lowering of Systolic Hypertension (AGELESS): a randomized controlled trial. J Hum Hypertens. 2009:doi: 10.1038/jhh.2009.1107.
  • 24
    Gavras HP. Issues in hypertension: drug tolerability and special populations. Am J Hypertens. 2001;14:231S236S.
  • 25
    Parish RC, Miller LJ. Adverse effects of angiotensin converting enzyme (ACE) inhibitors. An update. Drug Saf. 1992;7:1431.
  • 26
    Goldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol. 1995;75:793795.
  • 27
    MacKinnon M, Shurraw S, Akbari A, et al. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data. Am J Kidney Dis. 2006;48:820.
  • 28
    Karlberg BE. Cough and inhibition of the renin-angiotensin system. J Hypertens Suppl. 1993;11:S49S52.
  • 29
    Miller DR, Oliveria SA, Berlowitz DR, et al. Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors. Hypertension. 2008;51:16241630.
  • 30
    Kostis JB, Packer M, Black HR, et al. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens. 2004;17:103111.
  • 31
    Reardon LC, Macpherson DS. Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry? Arch Intern Med. 1998;158:2632.
  • 32
    Azizi M, Webb R, Nussberger J, et al. Renin inhibition with aliskiren: where are we now, and where are we going? J Hypertens. 2006;24:243256.
  • 33
    Gradman AH, Traub D. The efficacy of aliskiren, a direct renin inhibitor, in the treatment of hypertension. Rev Cardiovasc Med. 2007;8(suppl 2):S22S30.
  • 34
    Weir MR, Rolfe MR. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors. Clin J Am Soc Nephrol. 2010: doi: 10.2215/CJN.07821109.
  • 35
    Chrysant SG, Murray AV, Hoppe UC, et al. Incidence of hyperkalemia with aliskiren/valsartan combination in hypertensive patients with mild to moderate renal impairment and patients with normal renal function: a 54-week retrospective analysis. J Clin Hypertens. 2010;12:A30 (Abstract PO-29).
  • 36
    Burnier M, Hess B, Greminger P, et al. Determinants of persistence in hypertensive patients treated with irbesartan: results of a postmarketing survey. BMC Cardiovasc Disord. 2005;5:13.
  • 37
    Gregoire JP, Moisan J, Guibert R, et al. Determinants of discontinuation of new courses of antihypertensive medications. J Clin Epidemiol. 2002;55:728735.
  • 38
    Wogen J, Kreilick CA, Livornese RC, et al. Patient adherence with amlodipine, lisinopril, or valsartan therapy in a usual-care setting. J Manag Care Pharm. 2003;9:424429.
  • 39
    Thaker D, Frech F, Gause D, et al. Patient compliance and persistency with antihypertensive agents: a comparison of agents in different therapeutic classes. Am J Hypertens. 2005;18:222A (Abstract P-589).
  • 40
    Hoer A, Gothe H, Khan ZM, et al. Persistence and adherence with antihypertensive drug therapy in a German sickness fund population. J Hum Hypertens. 2007;21:744746.
  • 41
    Gregoire JP, Moisan J, Guibert R, et al. Tolerability of antihypertensive drugs in a community-based setting. Clin Ther. 2001;23:715726.
  • 42
    Black HR, Graff A, Shute D, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril. J Hum Hypertens. 1997;11:483489.